首页 > 最新文献

Deutsche Medizinische Wochenschrift最新文献

英文 中文
Erhöhen Depressionen das Krebsrisiko? 抑郁症增加患癌症的风险吗?
4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-09-01 DOI: 10.1055/a-1986-0775
Drug Prescribing for Patients with Chronic Kidney Disease in General Practice: a Cross-Sectional Study
慢性肾病患者的药物处方:一项横断面研究
{"title":"Erhöhen Depressionen das Krebsrisiko?","authors":"","doi":"10.1055/a-1986-0775","DOIUrl":"https://doi.org/10.1055/a-1986-0775","url":null,"abstract":"Drug Prescribing for Patients with Chronic Kidney Disease in General Practice: a Cross-Sectional Study","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135346937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Artificial Intelligence for computer-aided leukemia diagnostics]. [用于计算机辅助白血病诊断的人工智能]。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-09-01 Epub Date: 2023-08-23 DOI: 10.1055/a-1965-7044
Christian Matek, Carsten Marr, Michael von Bergwelt-Baildon, Karsten Spiekermann

The manual examination of blood and bone marrow specimens for leukemia patients is time-consuming and limited by intra- and inter-observer variance. The development of AI algorithms for leukemia diagnostics requires high-quality sample digitization and reliable annotation of large datasets. Deep learning-based algorithms using these datasets attain human-level performance for some well-defined, clinically relevant questions such as the blast character of cells. Methods such as multiple - instance - learning allow predicting diagnoses from a collection of leukocytes, but are more data-intensive. Using "explainable AI" methods can make the prediction process more transparent and allow users to verify the algorithm's predictions. Stability and robustness analyses are necessary for routine application of these algorithms, and regulatory institutions are developing standards for this purpose. Integrated diagnostics, which link different diagnostic modalities, offer the promise of even greater accuracy but require more extensive and diverse datasets.

白血病患者的血液和骨髓标本的手动检查是耗时的,并且受到观察者内部和观察者之间差异的限制。白血病诊断人工智能算法的开发需要高质量的样本数字化和大数据集的可靠注释。使用这些数据集的基于深度学习的算法在一些定义明确的临床相关问题(如细胞的爆炸特性)上达到了人类水平的性能。像多实例学习这样的方法可以从白细胞的集合中预测诊断,但数据更密集。使用“可解释的人工智能”方法可以使预测过程更加透明,并允许用户验证算法的预测。稳定性和稳健性分析对于这些算法的日常应用是必要的,监管机构正在为此制定标准。集成诊断将不同的诊断模式联系起来,有望提供更高的准确性,但需要更广泛和多样化的数据集。
{"title":"[Artificial Intelligence for computer-aided leukemia diagnostics].","authors":"Christian Matek,&nbsp;Carsten Marr,&nbsp;Michael von Bergwelt-Baildon,&nbsp;Karsten Spiekermann","doi":"10.1055/a-1965-7044","DOIUrl":"10.1055/a-1965-7044","url":null,"abstract":"<p><p>The manual examination of blood and bone marrow specimens for leukemia patients is time-consuming and limited by intra- and inter-observer variance. The development of AI algorithms for leukemia diagnostics requires high-quality sample digitization and reliable annotation of large datasets. Deep learning-based algorithms using these datasets attain human-level performance for some well-defined, clinically relevant questions such as the blast character of cells. Methods such as multiple - instance - learning allow predicting diagnoses from a collection of leukocytes, but are more data-intensive. Using \"explainable AI\" methods can make the prediction process more transparent and allow users to verify the algorithm's predictions. Stability and robustness analyses are necessary for routine application of these algorithms, and regulatory institutions are developing standards for this purpose. Integrated diagnostics, which link different diagnostic modalities, offer the promise of even greater accuracy but require more extensive and diverse datasets.</p>","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":"148 17","pages":"1108-1112"},"PeriodicalIF":0.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10069298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Advanced non-small cell lung cancer - pioneer in personalized oncology]. [晚期癌症-个性化肿瘤学的先驱]。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-09-01 DOI: 10.1055/a-1935-1939
Felix Carl Saalfeld, Daniela E Aust, Martin Wermke

In no other cancer is clinical practice as close to the ideals of personalized oncology as in the treatment of non-small cell lung cancer (NSCLC). Here, we briefly outline the basic principles of molecular analysis. The focus of the article is on the clinical utility of targeted therapy. Finally, we highlight the challenges for medical staff and structural solutions reflecting the situation in Germany.

在任何其他癌症中,临床实践都不像在治疗癌症(NSCLC)中那样接近个性化肿瘤学的理想。在这里,我们简要介绍一下分子分析的基本原理。本文的重点是靶向治疗的临床应用。最后,我们强调了医务人员面临的挑战以及反映德国局势的结构性解决方案。
{"title":"[Advanced non-small cell lung cancer - pioneer in personalized oncology].","authors":"Felix Carl Saalfeld,&nbsp;Daniela E Aust,&nbsp;Martin Wermke","doi":"10.1055/a-1935-1939","DOIUrl":"10.1055/a-1935-1939","url":null,"abstract":"<p><p>In no other cancer is clinical practice as close to the ideals of personalized oncology as in the treatment of non-small cell lung cancer (NSCLC). Here, we briefly outline the basic principles of molecular analysis. The focus of the article is on the clinical utility of targeted therapy. Finally, we highlight the challenges for medical staff and structural solutions reflecting the situation in Germany.</p>","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":"148 18","pages":"1166-1173"},"PeriodicalIF":0.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10201043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Alcoholic hepatitis - current and future treatment approaches]. [酒精性肝炎-当前和未来的治疗方法]。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-09-01 Epub Date: 2023-08-23 DOI: 10.1055/a-1941-7187
Philipp Kasper, Münevver Demir

Acute severe alcoholic hepatitis is a serious disease with poor prognosis. As a result of an improved understanding of the underlying pathomechanisms, a variety of new, innovative therapeutic modalities are currently being investigated that may help to improve prognosis. New approaches include the application of anti-inflammatory agents (e.g., interleukin-1 inhibitors), modifications of the gut-liver axis via fecal microbiome transfer or the administration of non-absorbable antibiotics (e.g., rifaximin), and drugs to enhance hepatocellular regeneration (e.g., interleukin-22 agonists). This article describes current management concepts of alcoholic hepatitis and provides an overview of new potential treatment approaches.

急性重型酒精性肝炎是一种预后不良的严重疾病。由于对潜在病理机制的理解有所提高,目前正在研究各种新的、创新的治疗模式,这些模式可能有助于改善预后。新的方法包括应用抗炎药(如白细胞介素-1抑制剂)、通过粪便微生物组转移或给予不可吸收抗生素(如利福昔明)来改变肠肝轴,以及增强肝细胞再生的药物(如白介素-22激动剂)。本文介绍了目前酒精性肝炎的管理概念,并概述了新的潜在治疗方法。
{"title":"[Alcoholic hepatitis - current and future treatment approaches].","authors":"Philipp Kasper,&nbsp;Münevver Demir","doi":"10.1055/a-1941-7187","DOIUrl":"10.1055/a-1941-7187","url":null,"abstract":"<p><p>Acute severe alcoholic hepatitis is a serious disease with poor prognosis. As a result of an improved understanding of the underlying pathomechanisms, a variety of new, innovative therapeutic modalities are currently being investigated that may help to improve prognosis. New approaches include the application of anti-inflammatory agents (e.g., interleukin-1 inhibitors), modifications of the gut-liver axis via fecal microbiome transfer or the administration of non-absorbable antibiotics (e.g., rifaximin), and drugs to enhance hepatocellular regeneration (e.g., interleukin-22 agonists). This article describes current management concepts of alcoholic hepatitis and provides an overview of new potential treatment approaches.</p>","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":"148 17","pages":"1095-1101"},"PeriodicalIF":0.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10063066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Management of drug-resistant tuberculosis]. [耐药结核病的管理]。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-09-01 Epub Date: 2023-09-15 DOI: 10.1055/a-1939-0000
Christoph Lange

The spread of multidrug-resistant Mycobacterium tuberculosis bacteria jeopardizes tuberculosis control, especially in the WHO Europe region. Following the availability of novel drugs and treatment regimens the World Health Organization has updated management recommendations for patients affected by drug-resistant tuberculosis. These novel recommendations include a significant reduction in the duration of therapy. This review presents the epidemiology and diagnostics of antibiotic-resistant tuberculosis as well as up-to-date treatment recommendations.

耐多药结核分枝杆菌的传播危及结核病控制,特别是在世界卫生组织欧洲地区。在获得新药和治疗方案后,世界卫生组织更新了对耐药结核病患者的管理建议。这些新颖的建议包括显著缩短治疗时间。这篇综述介绍了抗生素耐药性结核病的流行病学和诊断,以及最新的治疗建议。
{"title":"[Management of drug-resistant tuberculosis].","authors":"Christoph Lange","doi":"10.1055/a-1939-0000","DOIUrl":"10.1055/a-1939-0000","url":null,"abstract":"<p><p>The spread of multidrug-resistant Mycobacterium tuberculosis bacteria jeopardizes tuberculosis control, especially in the WHO Europe region. Following the availability of novel drugs and treatment regimens the World Health Organization has updated management recommendations for patients affected by drug-resistant tuberculosis. These novel recommendations include a significant reduction in the duration of therapy. This review presents the epidemiology and diagnostics of antibiotic-resistant tuberculosis as well as up-to-date treatment recommendations.</p>","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":"148 19","pages":"1236-1241"},"PeriodicalIF":0.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10309572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatitis C: nie zu früh für eine Behandlung 肝炎:从不是早期治疗
4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-08-01 DOI: 10.1055/a-2034-2423
Jahrzehnte erhielten Erkrankte mit einer chronischen Hepatitis C eine interferonbasierte Behandlung, die nicht nur nebenwirkungsreich, sondern darüber hinaus wenig wirksam war. Direkt antiviral wirksame Medikamente (DAA) haben seit 2014 das Management grundlegend verändert. Die Studiengruppe überprüfte retrospektiv die Effekte auf hepatische und nicht hepatische Komplikationen sowie die Mortalität. Verglichen mit Unbehandelten profitierten Behandelte von den DAA deutlich.
几十年来,患者一直接受带有慢性肝炎(肝炎)的治疗。这项治疗不仅产生了副作用,而且没有什么疗效。自2014年以来对该机制的管理发生了重大变化。调查小组审查了怀疑者对希帕尔病菌和死亡率的影响,而不是希帕尔病菌。而被告的尸体被发现
{"title":"Hepatitis C: nie zu früh für eine Behandlung","authors":"","doi":"10.1055/a-2034-2423","DOIUrl":"https://doi.org/10.1055/a-2034-2423","url":null,"abstract":"Jahrzehnte erhielten Erkrankte mit einer chronischen Hepatitis C eine interferonbasierte Behandlung, die nicht nur nebenwirkungsreich, sondern darüber hinaus wenig wirksam war. Direkt antiviral wirksame Medikamente (DAA) haben seit 2014 das Management grundlegend verändert. Die Studiengruppe überprüfte retrospektiv die Effekte auf hepatische und nicht hepatische Komplikationen sowie die Mortalität. Verglichen mit Unbehandelten profitierten Behandelte von den DAA deutlich.","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136065098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Cardiovascular prevention: Better safe than sorry]. [心血管预防:安全总比遗憾好]。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-08-01 Epub Date: 2023-08-04 DOI: 10.1055/a-1922-1626
Stefan Frantz
{"title":"[Cardiovascular prevention: Better safe than sorry].","authors":"Stefan Frantz","doi":"10.1055/a-1922-1626","DOIUrl":"10.1055/a-1922-1626","url":null,"abstract":"","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":"148 16","pages":"997"},"PeriodicalIF":0.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10302347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Diabetes in old age]. [老年糖尿病]。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-08-01 Epub Date: 2023-07-21 DOI: 10.1055/a-1801-5971
Jürgen Wernecke, Anke Bahrmann

Diabetes is one of the most common chronical diseases in old age. More than 50 % of the patients are older than 65 years. Elderly with diabetes often suffer from functional or cognitive deficits that should be registered in therapy. These include special geriatric syndromes like memory failure, frailty, falls, immobility or higher vulnerability for drug interactions. Comorbidity und functional deficits influence each other. Simple therapy regimens should be preferred to avoid polypharmacia and to preserve patient's independence. Specific risks of old age under new antidiabetic drugs should be noted. Check-ups and treatment of diabetic complications, especially the diabetic foot should be consequently induced considerating age-specific features.

糖尿病是老年人最常见的慢性疾病之一。超过50 % 大多数患者年龄在65岁以上。患有糖尿病的老年人经常患有功能或认知缺陷,应在治疗中进行登记。其中包括特殊的老年综合征,如记忆力减退、虚弱、跌倒、不动或更容易受到药物相互作用的影响。合并症和功能缺陷相互影响。应首选简单的治疗方案,以避免多药治疗并保持患者的独立性。应注意新型抗糖尿病药物治疗老年的具体风险。糖尿病并发症,尤其是糖尿病足的检查和治疗应考虑到年龄的特殊性。
{"title":"[Diabetes in old age].","authors":"Jürgen Wernecke,&nbsp;Anke Bahrmann","doi":"10.1055/a-1801-5971","DOIUrl":"10.1055/a-1801-5971","url":null,"abstract":"<p><p>Diabetes is one of the most common chronical diseases in old age. More than 50 % of the patients are older than 65 years. Elderly with diabetes often suffer from functional or cognitive deficits that should be registered in therapy. These include special geriatric syndromes like memory failure, frailty, falls, immobility or higher vulnerability for drug interactions. Comorbidity und functional deficits influence each other. Simple therapy regimens should be preferred to avoid polypharmacia and to preserve patient's independence. Specific risks of old age under new antidiabetic drugs should be noted. Check-ups and treatment of diabetic complications, especially the diabetic foot should be consequently induced considerating age-specific features.</p>","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":"148 15","pages":"974-987"},"PeriodicalIF":0.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9879152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Renal insufficiency and cardiovascular risk]. [肾功能不全和心血管风险]。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-08-01 Epub Date: 2023-08-04 DOI: 10.1055/a-1922-1719
Christoph Wanner, Anna Laura Herzog, Jule Pinter

Patients with chronic renal insufficiency often show symptoms that are atypical for cardiovascular problems. The correct interpretation of the symptoms is crucial in order to correctly assess the risk of a heart-related emergency and to take preventive measures and initiate the right therapy. Biomarkers such as NT-proBNP, troponin T or hsCRP (highly sensitive CRP) are independent predictors of mortality, but do not replace instrument-based diagnostics. Patients with renal insufficiency often have stiff vessels which, due to the premature reflection of the pulse wave, can lead to left ventricular dysfunction and ultimately to heart failure.

慢性肾功能不全患者通常表现出心血管问题不典型的症状。正确解释症状对于正确评估心脏相关紧急情况的风险、采取预防措施和开始正确的治疗至关重要。生物标志物,如NT-proBNP、肌钙蛋白T或hsCRP(高度敏感的CRP)是死亡率的独立预测因子,但不能取代基于仪器的诊断。肾功能不全患者通常血管僵硬,由于脉搏波的过早反射,可导致左心室功能障碍,最终导致心力衰竭。
{"title":"[Renal insufficiency and cardiovascular risk].","authors":"Christoph Wanner,&nbsp;Anna Laura Herzog,&nbsp;Jule Pinter","doi":"10.1055/a-1922-1719","DOIUrl":"10.1055/a-1922-1719","url":null,"abstract":"<p><p>Patients with chronic renal insufficiency often show symptoms that are atypical for cardiovascular problems. The correct interpretation of the symptoms is crucial in order to correctly assess the risk of a heart-related emergency and to take preventive measures and initiate the right therapy. Biomarkers such as NT-proBNP, troponin T or hsCRP (highly sensitive CRP) are independent predictors of mortality, but do not replace instrument-based diagnostics. Patients with renal insufficiency often have stiff vessels which, due to the premature reflection of the pulse wave, can lead to left ventricular dysfunction and ultimately to heart failure.</p>","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":"148 16","pages":"1020-1024"},"PeriodicalIF":0.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10302350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Typ-2-Diabetes: SGLT2-Inhibitoren und DPP4-Inhibitoren im Vergleich 2型糖尿病:斯glt2抑制剂和dpp4抑制剂比较起来
4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-08-01 DOI: 10.1055/a-2058-1545
SGLT2-Inhibitoren und DPP4-Inhibitoren kommen heute in der Behandlung des Typ-2-Diabetes regelhaft zum Einsatz. Dabei stellt sich vor einer individuellen Therapieentscheidung die Frage nach der Rolle der Höhe des prätherapeutischen HbA1c-Wertes für Sicherheit und Wirksamkeit beider Antidiabetika. D’Andrea et al. wollten Antworten finden und haben eine groß angelegte Vergleichsstudie zur Frage durchgeführt.
蜂毒抑制剂和dpp4抑制剂如今在治疗2型糖尿病时普遍使用。在这一切面前,一个单独的治疗决定是问什麽hba1c产前hba1c对于两种抗糖尿病药物的安全性和功效的作用。达德里要找到答案然后做了一个重要的对比研究。
{"title":"Typ-2-Diabetes: SGLT2-Inhibitoren und DPP4-Inhibitoren im Vergleich","authors":"","doi":"10.1055/a-2058-1545","DOIUrl":"https://doi.org/10.1055/a-2058-1545","url":null,"abstract":"SGLT2-Inhibitoren und DPP4-Inhibitoren kommen heute in der Behandlung des Typ-2-Diabetes regelhaft zum Einsatz. Dabei stellt sich vor einer individuellen Therapieentscheidung die Frage nach der Rolle der Höhe des prätherapeutischen HbA1c-Wertes für Sicherheit und Wirksamkeit beider Antidiabetika. D’Andrea et al. wollten Antworten finden und haben eine groß angelegte Vergleichsstudie zur Frage durchgeführt.","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":"75 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136065104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Deutsche Medizinische Wochenschrift
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1